Ratings Microba Life Sciences Limited

Equities

MAP

AU0000209868

Market Closed - Australian S.E. Other stock markets 05:34:40 10/05/2024 am IST			5-day change	1st Jan Change
0.175 ^AUD	0.00%		-5.41%	-2.78%

23/04	Microba's Revenue Climbs 297% in Fiscal Q3	MT
10/04	Microba Life Sciences Secures AU$6 Million Tax Rebate for Fiscal Year 2023; Shares Fall 5%	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
With an enterprise value anticipated at 4.9 times the sales for the current fiscal year, the company turns out to be overvalued.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	ESG Refinitiv
MICROBA LIFE SCIENCES LIMITED	-2.78%	51.79M	-
SONIC HEALTHCARE LIMITED	-16.58%	8.44B	B+
RADNET, INC.	+54.96%	3.96B	C+
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-39.78%	2.52B	B-
SYNLAB AG	-10.16%	2.44B	-
DR. LAL PATHLABS LIMITED	-8.91%	2.22B	B-
NEOGENOMICS, INC.	-2.60%	1.98B	C-
FLEURY S.A.	-19.73%	1.58B	A-
DIAN DIAGNOSTICS GROUP CO.,LTD.	-38.30%	1.3B	C+
METROPOLIS HEALTHCARE LIMITED	+2.19%	1.05B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes